Catch A Glimpse of OrganaBio at ISCT2023

Watch a short clip of OrganaBio’s Chief Business Officer, Priya Baraniak, Ph.D. and VP, Operations, J. Dominic Mancini #LiveWithChaudhrey at #ISCT2023 Paris (June 1, Day 2) to learn about OrganaBio, our services for the cell and gene therapy space, and what makes us unique. At ISCT, attendees were given the opportunity to learn more about […]
Case Study: Delivering RUO & GMP LeukoPAC™ collections to Singapore

INTRODUCTION The monoclonal antibodies (mAbs) daratumumab, and elotuzumab have been approved by the US Food and Drug Administration for treating multiple myeloma (MM) in 2015. Although clinical responses have been promising, most patients’ disease eventually progresses [1]. One of the potential anti-tumor mechanisms of mAbs in MM patients is antibody-dependent cellular cytotoxicity (ADCC) which is […]
The OrganaBio method for cultivation of a highly recallable leukapheresis donor pool

OrganaBio and its wholly-owned leukapheresis collection subsidiary, HemaCenter, have designed processes and procedures to curate and maintain a highly recallable donor pool. Access to robust, reliable cellular starting materials is critical to the success of a cell therapy program, and donor recallability is one of the largest challenges facing cell therapy developers who rely on […]